Abstract
Humanized antibodies are constructed by CDR grafting, while retaining those murine framework residues that influence the antigen-binding activity. To reduce the immunogenicity of CDR-grafted humanized antibodies, the murine content in the CDR-grafted humanized antibodies is minimized through SDR grafting. Within each CDR, there are more variable positions that are directly involved in the interaction with antigen, i.e., specificity-determining residues (SDRs), whereas there are more conserved residues that maintain the conformations of CDRs loops. SDRs may be identified from the 3D structure of the antigen–antibody complex and/or the mutational analysis of the CDRs. An SDR-grafted humanized antibody is constructed by grafting the SDRs and the residues maintaining the conformations of the CDRs onto human template, and its immunogenic potential is evaluated by measuring the reactivity to the sera from patients who had been immunized with the parental antibody.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Shawler DL et al (1985) Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135:1530–1535
Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15:42–52
Morrison SL et al (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851–6855
Bell M, Kamm M (2000) Aliment Phamacol Ther 14:501–514
Jones PT et al (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525
Riechmann L et al (1988) Reshaping human antibodies for therapy. Nature 332:323–327
Queen C et al (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86:10029–10033
Winter G, Harris WJ (1993) Immunol Today 14:243–246
Reichert JM (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073–1078
Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3–10
Glaser SM et al (1992) Dissection of the combining site in a humanized anti-Tac antibody. J Immunol 149:2607–2614
Padlan EA (1994) Anatomy of an antibody molecule. Mol Immunol 31:169–217
Padlan EA, Abergel C, Tipper JP (1995) Identification of specificity-determining residues in antibodies. FASEB J 9:133–139
Tamura M et al (2000) Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 164:1432–1441
De Pascalis R et al (2002) Grafting of “abbreviated” CDRs containing specificity determining residues (SDRs) essential for ligand contact to engineer a less immunogenic humanized mAb. J Immunol 169:3076–3084
Gonzales NR et al (2003) Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol Immunol 40:337–349
Yoon SO et al (2006) Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J Biol Chem 281:6985–6992
Kim K-S, Myung P-K, Hong HJ (2010) Construction of a humanized antibody to hepatitis B surface antigen by specificity determining residues (SDR)-grafting and de-immunization. Biochem Biophys Res Commun 396:231–237
Chi S-W et al (2007) Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-Âopening mechanism. Proc Natl Acad Sci U S A 104:9230–9235
Gonzales NR et al (2002) Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies. J Immunol Methods 268:197–210
Singer II et al (1993) Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. J Immunol 150:2844–2857
Rosok MJ et al (1996) A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J Biol Chem 271:22611–22618
Caldas C et al (2000) Design and synthesis of germline-based hemi-humanized single chain Fv against the CD18 surface antigen. Protein Eng 13:353–360
Tempest PR et al (1995) Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. Int J Biol Macromol 17:37–42
Karlsson K, Larsson A (2004) Affinity measurement using surface plasmon resonance. In: Benny KCLo (ed) Antibody engineering: methods and protocols, methods in molecular biology, vol 248. Humana, Totowa, NJ, pp 389–416
Blake RC II, Blake DA (2004) Kinetic exclusion assays to study high-affinity binding interactions in homogenous solutions. In: Benny KCLo (ed) Antibody engineering: methods and protocols, methods in molecular biology, vol 248. Humana, Totowa, NJ, pp 417–430
Acknowledgments
This work was supported by the Global Frontier Project grant (NRF-M1AXA-002-2010-0029762) of National Research Foundation funded by the Ministry of Education, Science and Technology of Korea.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kim, J.H., Hong, H.J. (2012). Humanization by CDR Grafting and Specificity-Determining Residue Grafting. In: Chames, P. (eds) Antibody Engineering. Methods in Molecular Biology, vol 907. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-974-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-974-7_13
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-973-0
Online ISBN: 978-1-61779-974-7
eBook Packages: Springer Protocols